The efficacy of myo-inositol supplementation to reduce the incidence of gestational diabetes: a meta-analysis

作者全名："Liu, Qinxin; Liu, Zucui"

作者地址："[Liu, Qinxin; Liu, Zucui] Chongqing Med Univ, Dept Obstet & Gynecol, Banan Hosp, Chongqing, Peoples R China"

通信作者："Liu, ZC (通讯作者)，Chongqing Med Univ, Dept Obstet & Gynecol, Banan Hosp, Chongqing, Peoples R China."

来源：GYNECOLOGICAL ENDOCRINOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000796428600001

JCR分区：Q3

影响因子：2

年份：2022

卷号：38

期号：6

开始页：450

结束页：454

文献类型：Article

关键词：Gestational diabetes; myo-inositol supplementation; randomized controlled trials; meta-analysis

摘要："Introduction Myo-inositol supplementation is used to reduce the incidence of gestational diabetes, but its efficacy is not well established. This meta-analysis aims to explore the influence of myo-inositol supplementation on the prevention of gestational diabetes. Methods This meta-analysis has been conducted up to March 2022 to identify randomized clinical trials comparing the efficacy of myo-inositol supplementation to prevent gestational diabetes. Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systemically. Results We have included eight RCTs in this meta-analysis. Compared with control group in pregnant women, myo-inositol supplementation was found to significantly decrease the incidence of gestational diabetes (OR = 0.40; 95% CI = 0.19 to 0.84; p = .01), 2-h glucose OGTT (SMD = -0.22; 95% CI = -0.41 to -0.02; p = .03), HOMA-IR (SMD = -0.25; 95% CI = -0.42 to -0.08; p = .004) and preterm delivery (OR = 0.41; 95% CI = 0.23 to 0.73; p = .003), but demonstrated no obvious impact on gestational age at birth (SMD = 0.12; 95% CI = -0.05 to 0.29; p = .18) or birth weight (SMD = -0.04; 95% CI = -0.20 to 0.13; p = .68). Conclusions Myo-inositol supplementation is effective to reduce the incidence of gestational diabetes, 2-h glucose OGTT, HOMA-IR and preterm delivery, which suggested that myo-inositol supplementation should be recommended to prevent gestational diabetes."

基金机构：　

基金资助正文：